Technical Analysis for XBIO - Xenetic Biosciences, Inc.

Grade Last Price % Change Price Change
grade F 2.0 -5.21% -0.11
XBIO closed down 5.21 percent on Tuesday, March 19, 2019, on 49 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Mar 29

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical XBIO trend table...

Date Alert Name Type % Chg
Mar 19 Fell Below 50 DMA Bearish 0.00%
Mar 19 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 19 BB Squeeze Ended Range Expansion 0.00%
Mar 19 Oversold Stochastic Weakness 0.00%
Mar 18 Fell Below 20 DMA Bearish -5.21%
Mar 18 1,2,3 Pullback Bullish Bullish Swing Setup -5.21%
Mar 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -5.21%
Mar 18 Bollinger Band Squeeze Range Contraction -5.21%
Mar 18 Oversold Stochastic Weakness -5.21%
Mar 15 Crossed Above 20 DMA Bullish -8.68%

Older signals for XBIO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company's platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company's technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company's lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Dialysis Chronic Kidney Disease Anemia Drug Therapies Refractory Acute Myeloid Leukemia Growth Factors Product Candidates
Is XBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.95
52 Week Low 1.37
Average Volume 71,947
200-Day Moving Average 2.6381
50-Day Moving Average 2.0705
20-Day Moving Average 2.178
10-Day Moving Average 2.138
Average True Range 0.2282
ADX 42.64
+DI 27.6486
-DI 12.4566
Chandelier Exit (Long, 3 ATRs ) 2.5654
Chandelier Exit (Short, 3 ATRs ) 2.6746
Upper Bollinger Band 2.3986
Lower Bollinger Band 1.9574
Percent B (%b) 0.1
BandWidth 20.257117
MACD Line 0.0078
MACD Signal Line 0.0304
MACD Histogram -0.0226
Fundamentals Value
Market Cap 17.44 Million
Num Shares 8.72 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -1.36
Price-to-Sales 6.14
Price-to-Book 1.60
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.25
Resistance 3 (R3) 2.27 2.22 2.21
Resistance 2 (R2) 2.22 2.16 2.21 2.19
Resistance 1 (R1) 2.11 2.12 2.08 2.08 2.18
Pivot Point 2.05 2.05 2.04 2.04 2.05
Support 1 (S1) 1.95 1.99 1.92 1.92 1.82
Support 2 (S2) 1.89 1.95 1.88 1.81
Support 3 (S3) 1.78 1.89 1.80
Support 4 (S4) 1.75